Loading
I-Mab
I-Mab is a biotech, founded in Shanghai and now based in Maryland, whose Claudin 18.2 and 4-1BB bispecific givastomig and CD73 antibody uliledlimab are in trials for stomach and lung cancer.
Also called: I-Mab Biopharma天境生物NASDAQ:IMAB
Overview
I-Mab develops immuno-oncology biologics and moved its headquarters to Rockville, Maryland after separating from its Chinese operations in 2024. Givastomig (TJ-CD4B), a Claudin 18.2 and 4-1BB bispecific, is in phase 1b/2 trials with nivolumab and chemotherapy in first-line gastric cancer. Uliledlimab (TJ004309) is a differentiated CD73 antibody studied with toripalimab in non-small cell lung cancer. The company also developed lemzoparlimab, a CD47 antibody once licensed to AbbVie.
Headquarters
Rockville, Maryland, US
Scorecard
All companies#420of 1245 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:IMAB
Stage
Public
Website
Founded
2016
Products
1Phase 3antibody (INN stem -mab; form not stated in the registry record)
Uliledlimab is an experimental investigational agent whose form is not stated in the registry from TJ Biopharma in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
Connected
2drugs
Phase 3antibody (INN stem -mab; form not stated in the registry record)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
i-mabbiopharma.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 193 company-less drugs to their makers and add 74 ma… · diff · file
Sourced, not expert-reviewed